Amgen's Xgeva faces FDA skepticism

The FDA isn't convinced that Amgen ($AMGN) needs another bone-metastasis indication for its new drug Xgeva. The drug is already approved to treat skeletal side effects in cancer patients, but Amgen is asking to market it as a preventive tool for men with advanced prostate cancer. The idea is that earlier use of Xgeva might stave off--or at least delay--development of bone metastases in those men. The other idea, of course, is that marketing the drug for that use could increase sales. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.